<abstracts-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/abstract/dtd" xmlns:dn="http://www.elsevier.com/xml/svapi/abstract/dtd" xmlns:ait="http://www.elsevier.com/xml/ani/ait" xmlns:ce="http://www.elsevier.com/xml/ani/common" xmlns:cto="http://www.elsevier.com/xml/cto/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/abstract/scopus_id/84968783394</prism:url><dc:identifier>SCOPUS_ID:84968783394</dc:identifier><eid>2-s2.0-84968783394</eid><prism:doi>10.1515/raon-2015-0027</prism:doi><dc:title>The prognostic value of whole blood SOX2, NANOG and OCT4 mRNA expression in advanced small-cell lung cancer</dc:title><prism:aggregationType>Journal</prism:aggregationType><srctype>j</srctype><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><citedby-count>13</citedby-count><prism:publicationName>Radiology and Oncology</prism:publicationName><dc:publisher>Association of Radiology and Oncology</dc:publisher><source-id>17866</source-id><prism:issn>15813207 13182099</prism:issn><prism:volume>50</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:startingPage>188</prism:startingPage><prism:endingPage>196</prism:endingPage><prism:pageRange>188-196</prism:pageRange><prism:coverDate>2016-06-01</prism:coverDate><openaccess>1</openaccess><openaccessFlag>true</openaccessFlag><dc:creator><author seq="1" auid="36992707400"><ce:initials>E.</ce:initials><ce:indexed-name>Sodja E.</ce:indexed-name><ce:surname>Sodja</ce:surname><ce:given-name>Eva</ce:given-name><preferred-name><ce:initials>E.</ce:initials><ce:indexed-name>Sodja E.</ce:indexed-name><ce:surname>Sodja</ce:surname><ce:given-name>Eva</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/36992707400</author-url><affiliation id="60078312" href="https://api.elsevier.com/content/affiliation/affiliation_id/60078312"/></author></dc:creator><dc:description><abstract xmlns="" original="y" xml:lang="eng"><publishercopyright>© 2016 Radiol Oncol.</publishercopyright><ce:para>The data on expression and clinical impact of cancer stem cell markers SOX2, NANOG and OCT4 in lung cancer is still lacking. The aim of our study was to compare SOX2, NANOG and OCT4 mRNA expression levels in whole blood between advanced small-cell lung cancer (SCLC) patients and healthy controls, and to correlate mRNA expression with progression-free survival (PFS) after first-line chemotherapy and overall survival (OS) in advanced SCLC patients. 50 advanced SCLC patients treated with standard chemotherapy and followed at University Clinic Golnik, Slovenia, between 2009 and 2013 were prospectively included. SOX2, NANOG and OCT4 mRNA expression levels were determined using TaqMan qPCR in whole blood collected prior to chemotherapy. Whole blood of 34 matched healthy individuals with no cancerous disease was also tested. SOX2 mRNA expression was significantly higher in whole blood of SCLC patients compared to healthy controls (p = 0.006). Significant correlation between SOX2 mRNA expression levels and the number of distant metastatic sites was established (p = 0.027). In survival analysis, patients with high SOX2 expression had shorter OS (p = 0.017) and PFS (p = 0.046). In multivariate Cox analysis, an independent value of high SOX2 expression for shorter OS (p = 0.002), but not PFS was confirmed. No significant differences were observed for NANOG or OCT4 expression levels when comparing SCLC patients and healthy controls neither when analysing survival outcomes in SCLC patients. SOX2 mRNA expression in whole blood might be a promising non-invasive marker for molecular screening of SCLC and important prognostic marker in advanced chemotherapy-treated SCLC patients, altogether indicating important role of cancer stem-like cell (CSC) regulators in cancer spread. Further evaluation of SOX2 as a possible screening/prognostic marker and a therapeutic target of SCLC is warranted.</ce:para></abstract></dc:description><link href="https://api.elsevier.com/content/abstract/scopus_id/84968783394" rel="self"/><link href="https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&amp;scp=84968783394&amp;origin=inward" rel="scopus"/><link href="https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&amp;scp=84968783394&amp;origin=inward" rel="scopus-citedby"/></coredata><affiliation id="60078312" href="https://api.elsevier.com/content/affiliation/affiliation_id/60078312"><affilname>Bolnišnica Golnik</affilname><affiliation-city>Golnik</affiliation-city><affiliation-country>Slovenia</affiliation-country></affiliation><affiliation id="60031106" href="https://api.elsevier.com/content/affiliation/affiliation_id/60031106"><affilname>University of Ljubljana</affilname><affiliation-city>Ljubljana</affiliation-city><affiliation-country>Slovenia</affiliation-country></affiliation><authors><author seq="1" auid="36992707400"><ce:initials>E.</ce:initials><ce:indexed-name>Sodja E.</ce:indexed-name><ce:surname>Sodja</ce:surname><ce:given-name>Eva</ce:given-name><preferred-name><ce:initials>E.</ce:initials><ce:indexed-name>Sodja E.</ce:indexed-name><ce:surname>Sodja</ce:surname><ce:given-name>Eva</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/36992707400</author-url><affiliation id="60078312" href="https://api.elsevier.com/content/affiliation/affiliation_id/60078312"/></author><author seq="2" auid="36939704200"><ce:initials>M.</ce:initials><ce:indexed-name>Rijavec M.</ce:indexed-name><ce:surname>Rijavec</ce:surname><ce:given-name>Matija</ce:given-name><preferred-name><ce:initials>M.</ce:initials><ce:indexed-name>Rijavec M.</ce:indexed-name><ce:surname>Rijavec</ce:surname><ce:given-name>Matija</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/36939704200</author-url><affiliation id="60078312" href="https://api.elsevier.com/content/affiliation/affiliation_id/60078312"/></author><author seq="3" auid="55241121900"><ce:initials>A.</ce:initials><ce:indexed-name>Koren A.</ce:indexed-name><ce:surname>Koren</ce:surname><ce:given-name>Ana</ce:given-name><preferred-name><ce:initials>A.</ce:initials><ce:indexed-name>Koren A.</ce:indexed-name><ce:surname>Koren</ce:surname><ce:given-name>Ana</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/55241121900</author-url><affiliation id="60078312" href="https://api.elsevier.com/content/affiliation/affiliation_id/60078312"/></author><author seq="4" auid="55883901600"><ce:initials>A.</ce:initials><ce:indexed-name>Sadikov A.</ce:indexed-name><ce:surname>Sadikov</ce:surname><ce:given-name>Aleksander</ce:given-name><preferred-name><ce:initials>A.</ce:initials><ce:indexed-name>Sadikov A.</ce:indexed-name><ce:surname>Sadikov</ce:surname><ce:given-name>Aleksander</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/55883901600</author-url><affiliation id="60031106" href="https://api.elsevier.com/content/affiliation/affiliation_id/60031106"/></author><author seq="5" auid="6701584602"><ce:initials>P.</ce:initials><ce:indexed-name>Korosec P.</ce:indexed-name><ce:surname>Korošec</ce:surname><ce:given-name>Peter</ce:given-name><preferred-name><ce:initials>P.</ce:initials><ce:indexed-name>Korošec P.</ce:indexed-name><ce:surname>Korošec</ce:surname><ce:given-name>Peter</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/6701584602</author-url><affiliation id="60078312" href="https://api.elsevier.com/content/affiliation/affiliation_id/60078312"/></author><author seq="6" auid="7004393140"><ce:initials>T.</ce:initials><ce:indexed-name>Cufer T.</ce:indexed-name><ce:surname>Cufer</ce:surname><ce:given-name>Tanja</ce:given-name><preferred-name><ce:initials>T.</ce:initials><ce:indexed-name>Cufer T.</ce:indexed-name><ce:surname>Cufer</ce:surname><ce:given-name>Tanja</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/7004393140</author-url><affiliation id="60078312" href="https://api.elsevier.com/content/affiliation/affiliation_id/60078312"/></author></authors><language xml:lang="eng"/><authkeywords><author-keyword>cancer stem cell markers</author-keyword><author-keyword>mRNA expression</author-keyword><author-keyword>NANOG</author-keyword><author-keyword>OCT4</author-keyword><author-keyword>prognosis</author-keyword><author-keyword>small-cell lung cancer</author-keyword><author-keyword>SOX2</author-keyword></authkeywords><idxterms/><subject-areas><subject-area code="2730" abbrev="MEDI">Oncology</subject-area><subject-area code="2741" abbrev="MEDI">Radiology, Nuclear Medicine and Imaging</subject-area></subject-areas><item xmlns=""><ait:process-info><ait:date-delivered year="2018" month="06" day="23" timestamp="2018-06-23T09:35:59.000059-04:00"/><ait:date-sort year="2016" month="06" day="01"/><ait:status type="core" state="update" stage="S300"/></ait:process-info><bibrecord><item-info><copyright type="Elsevier">Copyright 2017 Elsevier B.V., All rights reserved.</copyright><itemidlist><ce:doi>10.1515/raon-2015-0027</ce:doi><itemid idtype="PUI">610402482</itemid><itemid idtype="CAR-ID">650494546</itemid><itemid idtype="EMBASE">20160379380</itemid><itemid idtype="REAXYSCAR">20161201739</itemid><itemid idtype="SCP">84968783394</itemid><itemid idtype="SGR">84968783394</itemid></itemidlist><history><date-created year="2016" month="06" day="02" timestamp="BST 03:55:01"/></history><dbcollection>EMBASE</dbcollection><dbcollection>REAXYSCAR</dbcollection><dbcollection>Scopusbase</dbcollection></item-info><head><citation-info><citation-type code="ar"/><citation-language xml:lang="eng" language="English"/><abstract-language xml:lang="eng" language="English"/><author-keywords><author-keyword>cancer stem cell markers</author-keyword><author-keyword>mRNA expression</author-keyword><author-keyword>NANOG</author-keyword><author-keyword>OCT4</author-keyword><author-keyword>prognosis</author-keyword><author-keyword>small-cell lung cancer</author-keyword><author-keyword>SOX2</author-keyword></author-keywords></citation-info><citation-title><titletext xml:lang="eng" original="y" language="English">The prognostic value of whole blood SOX2, NANOG and OCT4 mRNA expression in advanced small-cell lung cancer</titletext></citation-title><author-group><author auid="36992707400" seq="1" type="auth"><ce:initials>E.</ce:initials><ce:indexed-name>Sodja E.</ce:indexed-name><ce:surname>Sodja</ce:surname><ce:given-name>Eva</ce:given-name><preferred-name><ce:initials>E.</ce:initials><ce:indexed-name>Sodja E.</ce:indexed-name><ce:surname>Sodja</ce:surname><ce:given-name>Eva</ce:given-name></preferred-name></author><author auid="36939704200" seq="2" type="auth"><ce:initials>M.</ce:initials><ce:indexed-name>Rijavec M.</ce:indexed-name><ce:surname>Rijavec</ce:surname><ce:given-name>Matija</ce:given-name><preferred-name><ce:initials>M.</ce:initials><ce:indexed-name>Rijavec M.</ce:indexed-name><ce:surname>Rijavec</ce:surname><ce:given-name>Matija</ce:given-name></preferred-name></author><author auid="55241121900" seq="3" type="auth"><ce:initials>A.</ce:initials><ce:indexed-name>Koren A.</ce:indexed-name><ce:surname>Koren</ce:surname><ce:given-name>Ana</ce:given-name><preferred-name><ce:initials>A.</ce:initials><ce:indexed-name>Koren A.</ce:indexed-name><ce:surname>Koren</ce:surname><ce:given-name>Ana</ce:given-name></preferred-name></author><author auid="6701584602" seq="5" type="auth" date-locked="2017-07-01T00:16:07.860"><ce:initials>P.</ce:initials><ce:indexed-name>Korosec P.</ce:indexed-name><ce:surname>Korošec</ce:surname><ce:given-name>Peter</ce:given-name><preferred-name><ce:initials>P.</ce:initials><ce:indexed-name>Korošec P.</ce:indexed-name><ce:surname>Korošec</ce:surname><ce:given-name>Peter</ce:given-name></preferred-name></author><author auid="7004393140" seq="6" type="auth"><ce:initials>T.</ce:initials><ce:indexed-name>Cufer T.</ce:indexed-name><ce:surname>Cufer</ce:surname><ce:given-name>Tanja</ce:given-name><preferred-name><ce:initials>T.</ce:initials><ce:indexed-name>Cufer T.</ce:indexed-name><ce:surname>Cufer</ce:surname><ce:given-name>Tanja</ce:given-name></preferred-name></author><affiliation afid="60078312" country="svn"><organization>University Clinic Golnik</organization><address-part>Golnik 36</address-part><city>Golnik</city><postal-code>4204</postal-code><affiliation-id afid="60078312"/><country>Slovenia</country></affiliation></author-group><author-group><author auid="55883901600" seq="4" type="auth"><ce:initials>A.</ce:initials><ce:indexed-name>Sadikov A.</ce:indexed-name><ce:surname>Sadikov</ce:surname><ce:given-name>Aleksander</ce:given-name><preferred-name><ce:initials>A.</ce:initials><ce:indexed-name>Sadikov A.</ce:indexed-name><ce:surname>Sadikov</ce:surname><ce:given-name>Aleksander</ce:given-name></preferred-name></author><affiliation afid="60031106" country="svn"><organization>University of Ljubljana</organization><organization>Faculty of Computer and Information Science</organization><city>Ljubljana</city><affiliation-id afid="60031106"/><country>Slovenia</country></affiliation></author-group><correspondence><person><ce:initials>E.</ce:initials><ce:indexed-name>Sodja E.</ce:indexed-name><ce:surname>Sodja</ce:surname><ce:given-name>Eva</ce:given-name></person><affiliation country="svn"><organization>University Clinic Golnik</organization><address-part>Golnik 36</address-part><city>Golnik</city><postal-code>4204</postal-code><country>Slovenia</country></affiliation></correspondence><abstracts><abstract original="y" xml:lang="eng"><publishercopyright>© 2016 Radiol Oncol.</publishercopyright><ce:para>The data on expression and clinical impact of cancer stem cell markers SOX2, NANOG and OCT4 in lung cancer is still lacking. The aim of our study was to compare SOX2, NANOG and OCT4 mRNA expression levels in whole blood between advanced small-cell lung cancer (SCLC) patients and healthy controls, and to correlate mRNA expression with progression-free survival (PFS) after first-line chemotherapy and overall survival (OS) in advanced SCLC patients. 50 advanced SCLC patients treated with standard chemotherapy and followed at University Clinic Golnik, Slovenia, between 2009 and 2013 were prospectively included. SOX2, NANOG and OCT4 mRNA expression levels were determined using TaqMan qPCR in whole blood collected prior to chemotherapy. Whole blood of 34 matched healthy individuals with no cancerous disease was also tested. SOX2 mRNA expression was significantly higher in whole blood of SCLC patients compared to healthy controls (p = 0.006). Significant correlation between SOX2 mRNA expression levels and the number of distant metastatic sites was established (p = 0.027). In survival analysis, patients with high SOX2 expression had shorter OS (p = 0.017) and PFS (p = 0.046). In multivariate Cox analysis, an independent value of high SOX2 expression for shorter OS (p = 0.002), but not PFS was confirmed. No significant differences were observed for NANOG or OCT4 expression levels when comparing SCLC patients and healthy controls neither when analysing survival outcomes in SCLC patients. SOX2 mRNA expression in whole blood might be a promising non-invasive marker for molecular screening of SCLC and important prognostic marker in advanced chemotherapy-treated SCLC patients, altogether indicating important role of cancer stem-like cell (CSC) regulators in cancer spread. Further evaluation of SOX2 as a possible screening/prognostic marker and a therapeutic target of SCLC is warranted.</ce:para></abstract></abstracts><source srcid="17866" type="j" country="deu"><sourcetitle>Radiology and Oncology</sourcetitle><sourcetitle-abbrev>Radiol. Oncol.</sourcetitle-abbrev><translated-sourcetitle xml:lang="eng">Radiology and Oncology</translated-sourcetitle><issn type="electronic">15813207</issn><issn type="print">13182099</issn><codencode>RONCE</codencode><volisspag><voliss volume="50" issue="2"/><pagerange first="188" last="196"/></volisspag><publicationyear first="2016"/><publicationdate><year>2016</year><month>06</month><day>01</day><date-text xfab-added="true">1 June 2016</date-text></publicationdate><website><ce:e-address type="email">http://www.degruyter.com/view/j/raon</ce:e-address></website><publisher><publishername>Association of Radiology and Oncology</publishername></publisher></source><enhancement><classificationgroup><classifications type="EMCLASS"><classification> <classification-code>15</classification-code> <classification-description>Chest Diseases, Thoracic Surgery and Tuberculosis</classification-description> </classification><classification> <classification-code>16</classification-code> <classification-description>Cancer</classification-description> </classification><classification> <classification-code>29</classification-code> <classification-description>Clinical and Experimental Biochemistry</classification-description> </classification><classification> <classification-code>37</classification-code> <classification-description>Drug Literature Index</classification-description> </classification></classifications><classifications type="ASJC"><classification>2730</classification><classification>2741</classification></classifications><classifications type="SUBJABBR"><classification>MEDI</classification></classifications></classificationgroup><chemicalgroup><chemicals source="esbd"><chemical><chemical-name>carboplatin</chemical-name><cas-registry-number>41575-94-4</cas-registry-number></chemical><chemical><chemical-name>cisplatin</chemical-name><cas-registry-number>15663-27-1</cas-registry-number><cas-registry-number>26035-31-4</cas-registry-number><cas-registry-number>96081-74-2</cas-registry-number></chemical><chemical><chemical-name>cyclophosphamide</chemical-name><cas-registry-number>50-18-0</cas-registry-number></chemical><chemical><chemical-name>epirubicin</chemical-name><cas-registry-number>56390-09-1</cas-registry-number><cas-registry-number>56420-45-2</cas-registry-number></chemical><chemical><chemical-name>etoposide</chemical-name><cas-registry-number>33419-42-0</cas-registry-number></chemical><chemical><chemical-name>vincristine</chemical-name><cas-registry-number>57-22-7</cas-registry-number></chemical></chemicals></chemicalgroup></enhancement></head><tail><bibliography refcount="51"><reference id="1"><ref-info><ref-title><ref-titletext>Cancer statistics 2014</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84892805731</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>R.</ce:initials><ce:indexed-name>Siegel R.</ce:indexed-name><ce:surname>Siegel</ce:surname></author><author seq="2"><ce:initials>J.</ce:initials><ce:indexed-name>Ma J.</ce:indexed-name><ce:surname>Ma</ce:surname></author><author seq="3"><ce:initials>Z.</ce:initials><ce:indexed-name>Zou Z.</ce:indexed-name><ce:surname>Zou</ce:surname></author><author seq="4"><ce:initials>A.</ce:initials><ce:indexed-name>Jemal A.</ce:indexed-name><ce:surname>Jemal</ce:surname></author></ref-authors><ref-sourcetitle>CA Cancer J Clin</ref-sourcetitle><ref-publicationyear first="2014"/><ref-volisspag><voliss volume="64"/><pagerange first="9" last="29"/></ref-volisspag></ref-info><ref-fulltext>Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics 2014. CA Cancer J Clin 2014; 64: 9-29</ref-fulltext></reference><reference id="2"><ref-info><ref-title><ref-titletext>Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84875804295</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>J.</ce:initials><ce:indexed-name>Ferlay J.</ce:indexed-name><ce:surname>Ferlay</ce:surname></author><author seq="2"><ce:initials>E.</ce:initials><ce:indexed-name>Steliarova-Foucher E.</ce:indexed-name><ce:surname>Steliarova-Foucher</ce:surname></author><author seq="3"><ce:initials>J.</ce:initials><ce:indexed-name>Lortet-Tieulent J.</ce:indexed-name><ce:surname>Lortet-Tieulent</ce:surname></author><author seq="4"><ce:initials>S.</ce:initials><ce:indexed-name>Rosso S.</ce:indexed-name><ce:surname>Rosso</ce:surname></author><author seq="5"><ce:initials>C.</ce:initials><ce:indexed-name>Jww C.</ce:indexed-name><ce:surname>Jww</ce:surname></author><author seq="6"><ce:initials>H.</ce:initials><ce:indexed-name>Comber H.</ce:indexed-name><ce:surname>Comber</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Eur J Cancer</ref-sourcetitle><ref-publicationyear first="2013"/><ref-volisspag><voliss volume="49"/><pagerange first="1374" last="1403"/></ref-volisspag></ref-info><ref-fulltext>Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Cancer 2013; 49: 1374-403</ref-fulltext></reference><reference id="3"><ref-info><ref-title><ref-titletext>Small cell lung cancer: New clinical recommendations and current status of biomarker assessment</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">80053271947</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>D.</ce:initials><ce:indexed-name>Planchard D.</ce:indexed-name><ce:surname>Planchard</ce:surname></author><author seq="2"><ce:initials>C.</ce:initials><ce:indexed-name>Le Pechoux C.</ce:indexed-name><ce:surname>Le Péchoux</ce:surname></author></ref-authors><ref-sourcetitle>Eur J Cancer</ref-sourcetitle><ref-publicationyear first="2011"/><ref-volisspag><voliss volume="47" issue="3"/><pagerange first="S272" last="S283"/></ref-volisspag></ref-info><ref-fulltext>Planchard D, Le Péchoux C. Small cell lung cancer: new clinical recommendations and current status of biomarker assessment. Eur J Cancer 2011; 47(Suppl 3): S272-83</ref-fulltext></reference><reference id="4"><ref-info><ref-title><ref-titletext>Advances in the treatment of small-cell lung cancer</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">79954574461</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>G.P.</ce:initials><ce:indexed-name>Kalemkerian G.P.</ce:indexed-name><ce:surname>Kalemkerian</ce:surname></author></ref-authors><ref-sourcetitle>Semin Respir Crit Care Med</ref-sourcetitle><ref-publicationyear first="2011"/><ref-volisspag><voliss volume="32"/><pagerange first="94" last="101"/></ref-volisspag></ref-info><ref-fulltext>Kalemkerian GP. Advances in the treatment of small-cell lung cancer. Semin Respir Crit Care Med 2011; 32: 94-101</ref-fulltext></reference><reference id="5"><ref-info><ref-title><ref-titletext>Prognostic factors differ by tumor stage for small cell lung cancer: A pooled analysis of north central cancer treatment group trials</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">67649184760</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>N.R.</ce:initials><ce:indexed-name>Foster N.R.</ce:indexed-name><ce:surname>Foster</ce:surname></author><author seq="2"><ce:initials>S.J.</ce:initials><ce:indexed-name>Mandrekar S.J.</ce:indexed-name><ce:surname>Mandrekar</ce:surname></author><author seq="3"><ce:initials>S.E.</ce:initials><ce:indexed-name>Schild S.E.</ce:indexed-name><ce:surname>Schild</ce:surname></author><author seq="4"><ce:initials>G.D.</ce:initials><ce:indexed-name>Nelson G.D.</ce:indexed-name><ce:surname>Nelson</ce:surname></author><author seq="5"><ce:initials>K.M.</ce:initials><ce:indexed-name>Rowland K.M.</ce:indexed-name><ce:surname>Rowland</ce:surname><ce:suffix>Jr.</ce:suffix></author><author seq="6"><ce:initials>R.L.</ce:initials><ce:indexed-name>Deming R.L.</ce:indexed-name><ce:surname>Deming</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Cancer</ref-sourcetitle><ref-publicationyear first="2009"/><ref-volisspag><voliss volume="115"/><pagerange first="2721" last="2731"/></ref-volisspag></ref-info><ref-fulltext>Foster NR, Mandrekar SJ, Schild SE, Nelson GD, Rowland KM Jr, Deming RL, et al. Prognostic factors differ by tumor stage for small cell lung cancer: a pooled analysis of North Central Cancer Treatment Group trials. Cancer 2009; 115: 2721-31</ref-fulltext></reference><reference id="6"><ref-info><ref-title><ref-titletext>Predictive value of multidrug resistance proteins, topoisomerases II and ERCC1 in small cell lung cancer: A systematic review</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">79955466333</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>L.</ce:initials><ce:indexed-name>Knez L.</ce:indexed-name><ce:surname>Knez</ce:surname></author><author seq="2"><ce:initials>E.</ce:initials><ce:indexed-name>Sodja E.</ce:indexed-name><ce:surname>Sodja</ce:surname></author><author seq="3"><ce:initials>I.</ce:initials><ce:indexed-name>Kern I.</ce:indexed-name><ce:surname>Kern</ce:surname></author><author seq="4"><ce:initials>M.</ce:initials><ce:indexed-name>KoSnik M.</ce:indexed-name><ce:surname>KoŜnik</ce:surname></author><author seq="5"><ce:initials>T.</ce:initials><ce:indexed-name>Cufer T.</ce:indexed-name><ce:surname>Cufer</ce:surname></author></ref-authors><ref-sourcetitle>Lung Cancer</ref-sourcetitle><ref-publicationyear first="2011"/><ref-volisspag><voliss volume="72"/><pagerange first="271" last="279"/></ref-volisspag></ref-info><ref-fulltext>Knez L, Sodja E, Kern I, KoŜnik M, Cufer T. Predictive value of multidrug resistance proteins, topoisomerases II and ERCC1 in small cell lung cancer: a systematic review. Lung Cancer 2011; 72: 271-9</ref-fulltext></reference><reference id="7"><ref-info><ref-title><ref-titletext>Impact of ERCC1 expression on treatment outcome in small-cell lung cancer patients treated with platinum-based chemotherapy</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84869496414</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>E.</ce:initials><ce:indexed-name>Sodja E.</ce:indexed-name><ce:surname>Sodja</ce:surname></author><author seq="2"><ce:initials>L.</ce:initials><ce:indexed-name>Knez L.</ce:indexed-name><ce:surname>Knez</ce:surname></author><author seq="3"><ce:initials>I.</ce:initials><ce:indexed-name>Kern I.</ce:indexed-name><ce:surname>Kern</ce:surname></author><author seq="4"><ce:initials>T.</ce:initials><ce:indexed-name>Ovcaricek T.</ce:indexed-name><ce:surname>Ovčariček</ce:surname></author><author seq="5"><ce:initials>A.</ce:initials><ce:indexed-name>Sadikov A.</ce:indexed-name><ce:surname>Sadikov</ce:surname></author><author seq="6"><ce:initials>T.</ce:initials><ce:indexed-name>Cufer T.</ce:indexed-name><ce:surname>Cufer</ce:surname></author></ref-authors><ref-sourcetitle>Eur J Cancer</ref-sourcetitle><ref-publicationyear first="2012"/><ref-volisspag><voliss volume="48"/><pagerange first="3378" last="3385"/></ref-volisspag></ref-info><ref-fulltext>Sodja E, Knez L, Kern I, Ovčariček T, Sadikov A, Cufer T. Impact of ERCC1 expression on treatment outcome in small-cell lung cancer patients treated with platinum-based chemotherapy. Eur J Cancer 2012; 48: 3378-85</ref-fulltext></reference><reference id="8"><ref-info><ref-title><ref-titletext>Stem cells for lung cancer?</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">20444424204</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>A.</ce:initials><ce:indexed-name>Berns A.</ce:indexed-name><ce:surname>Berns</ce:surname></author></ref-authors><ref-sourcetitle>Cell</ref-sourcetitle><ref-publicationyear first="2005"/><ref-volisspag><voliss volume="121"/><pagerange first="811" last="813"/></ref-volisspag></ref-info><ref-fulltext>Berns A. Stem cells for lung cancer? Cell 2005; 121: 811-3</ref-fulltext></reference><reference id="9"><ref-info><ref-title><ref-titletext>Lung cancer stem cells</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">47849127670</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>S.R.</ce:initials><ce:indexed-name>Pine S.R.</ce:indexed-name><ce:surname>Pine</ce:surname></author><author seq="2"><ce:initials>B.</ce:initials><ce:indexed-name>Marshall B.</ce:indexed-name><ce:surname>Marshall</ce:surname></author><author seq="3"><ce:initials>L.</ce:initials><ce:indexed-name>Varticovski L.</ce:indexed-name><ce:surname>Varticovski</ce:surname></author></ref-authors><ref-sourcetitle>Dis Markers</ref-sourcetitle><ref-publicationyear first="2008"/><ref-volisspag><voliss volume="24"/><pagerange first="257" last="266"/></ref-volisspag></ref-info><ref-fulltext>Pine SR, Marshall B, Varticovski L. Lung cancer stem cells. Dis Markers 2008; 24: 257-66</ref-fulltext></reference><reference id="10"><ref-info><ref-title><ref-titletext>Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">21344454219</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>D.</ce:initials><ce:indexed-name>Ponti D.</ce:indexed-name><ce:surname>Ponti</ce:surname></author><author seq="2"><ce:initials>A.</ce:initials><ce:indexed-name>Costa A.</ce:indexed-name><ce:surname>Costa</ce:surname></author><author seq="3"><ce:initials>N.</ce:initials><ce:indexed-name>Zaffaroni N.</ce:indexed-name><ce:surname>Zaffaroni</ce:surname></author><author seq="4"><ce:initials>G.</ce:initials><ce:indexed-name>Pratesi G.</ce:indexed-name><ce:surname>Pratesi</ce:surname></author><author seq="5"><ce:initials>G.</ce:initials><ce:indexed-name>Petrangolini G.</ce:indexed-name><ce:surname>Petrangolini</ce:surname></author><author seq="6"><ce:initials>D.</ce:initials><ce:indexed-name>Coradini D.</ce:indexed-name><ce:surname>Coradini</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Cancer Res</ref-sourcetitle><ref-publicationyear first="2005"/><ref-volisspag><voliss volume="65"/><pagerange first="5506" last="5511"/></ref-volisspag></ref-info><ref-fulltext>Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 2005; 65: 5506-11</ref-fulltext></reference><reference id="11"><ref-info><ref-title><ref-titletext>Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">33645026803</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>L.</ce:initials><ce:indexed-name>Patrawala L.</ce:indexed-name><ce:surname>Patrawala</ce:surname></author><author seq="2"><ce:initials>T.</ce:initials><ce:indexed-name>Calhoun T.</ce:indexed-name><ce:surname>Calhoun</ce:surname></author><author seq="3"><ce:initials>R.</ce:initials><ce:indexed-name>Schneider-Broussard R.</ce:indexed-name><ce:surname>Schneider-Broussard</ce:surname></author><author seq="4"><ce:initials>H.</ce:initials><ce:indexed-name>Li H.</ce:indexed-name><ce:surname>Li</ce:surname></author><author seq="5"><ce:initials>B.</ce:initials><ce:indexed-name>Bhatia B.</ce:indexed-name><ce:surname>Bhatia</ce:surname></author><author seq="6"><ce:initials>S.</ce:initials><ce:indexed-name>Tang S.</ce:indexed-name><ce:surname>Tang</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Oncogene</ref-sourcetitle><ref-publicationyear first="2006"/><ref-volisspag><voliss volume="25"/><pagerange first="1696" last="1708"/></ref-volisspag></ref-info><ref-fulltext>Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, Tang S, et al. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006; 25: 1696-708</ref-fulltext></reference><reference id="12"><ref-info><ref-title><ref-titletext>Identification of pancreatic cancer stem cells</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">33847052127</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>C.</ce:initials><ce:indexed-name>Li C.</ce:indexed-name><ce:surname>Li</ce:surname></author><author seq="2"><ce:initials>D.G.</ce:initials><ce:indexed-name>Heidt D.G.</ce:indexed-name><ce:surname>Heidt</ce:surname></author><author seq="3"><ce:initials>P.</ce:initials><ce:indexed-name>Dalerba P.</ce:indexed-name><ce:surname>Dalerba</ce:surname></author><author seq="4"><ce:initials>C.F.</ce:initials><ce:indexed-name>Burnat C.F.</ce:indexed-name><ce:surname>Burnat</ce:surname></author><author seq="5"><ce:initials>L.</ce:initials><ce:indexed-name>Zhang L.</ce:indexed-name><ce:surname>Zhang</ce:surname></author><author seq="6"><ce:initials>V.</ce:initials><ce:indexed-name>Adsay V.</ce:indexed-name><ce:surname>Adsay</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Cancer Res</ref-sourcetitle><ref-publicationyear first="2007"/><ref-volisspag><voliss volume="67"/><pagerange first="1030" last="1037"/></ref-volisspag></ref-info><ref-fulltext>Li C, Heidt DG, Dalerba P, Burnat CF, Zhang L, Adsay V, et al. Identification of pancreatic cancer stem cells. Cancer Res 2007; 67: 1030-7</ref-fulltext></reference><reference id="13"><ref-info><ref-title><ref-titletext>Identification and expansion of the tumorigenic lung cancer stem cell population</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">39449088496</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>A.</ce:initials><ce:indexed-name>Eramo A.</ce:indexed-name><ce:surname>Eramo</ce:surname></author><author seq="2"><ce:initials>F.</ce:initials><ce:indexed-name>Lotti F.</ce:indexed-name><ce:surname>Lotti</ce:surname></author><author seq="3"><ce:initials>G.</ce:initials><ce:indexed-name>Sette G.</ce:indexed-name><ce:surname>Sette</ce:surname></author><author seq="4"><ce:initials>E.</ce:initials><ce:indexed-name>Pilozzi E.</ce:indexed-name><ce:surname>Pilozzi</ce:surname></author><author seq="5"><ce:initials>M.</ce:initials><ce:indexed-name>Biffoni M.</ce:indexed-name><ce:surname>Biffoni</ce:surname></author><author seq="6"><ce:initials>A.</ce:initials><ce:indexed-name>Di Virgilio A.</ce:indexed-name><ce:surname>Di Virgilio</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Cell Death Differ</ref-sourcetitle><ref-publicationyear first="2008"/><ref-volisspag><voliss volume="15"/><pagerange first="504" last="514"/></ref-volisspag></ref-info><ref-fulltext>Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008; 15: 504-14</ref-fulltext></reference><reference id="14"><ref-info><ref-title><ref-titletext>Evidence that SOX2 overexpression is oncogenic in the lung</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">77956224492</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>Y.</ce:initials><ce:indexed-name>Lu Y.</ce:indexed-name><ce:surname>Lu</ce:surname></author><author seq="2"><ce:initials>C.</ce:initials><ce:indexed-name>Futtner C.</ce:indexed-name><ce:surname>Futtner</ce:surname></author><author seq="3"><ce:initials>J.R.</ce:initials><ce:indexed-name>Rock J.R.</ce:indexed-name><ce:surname>Rock</ce:surname></author><author seq="4"><ce:initials>X.</ce:initials><ce:indexed-name>Xu X.</ce:indexed-name><ce:surname>Xu</ce:surname></author><author seq="5"><ce:initials>W.</ce:initials><ce:indexed-name>Whitworth W.</ce:indexed-name><ce:surname>Whitworth</ce:surname></author><author seq="6"><ce:initials>H.</ce:initials><ce:indexed-name>Blm H.</ce:indexed-name><ce:surname>Blm</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>PLos One</ref-sourcetitle><ref-publicationyear first="2010"/><ref-volisspag><voliss volume="5"/><pagerange first="e11022"/></ref-volisspag></ref-info><ref-fulltext>Lu Y, Futtner C, Rock JR, Xu X, Whitworth W, Hogan BLM, et al. Evidence that SOX2 overexpression is oncogenic in the lung. PLos One 2010; 5: e11022</ref-fulltext></reference><reference id="15"><ref-info><ref-title><ref-titletext>Expression of Bmi1, FoxF1, Nanog, and γ-catenin in relation to hedgehog signaling pathway in human non-small-cell lung cancer</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84884820395</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>I.P.</ce:initials><ce:indexed-name>Gialmanidis I.P.</ce:indexed-name><ce:surname>Gialmanidis</ce:surname></author><author seq="2"><ce:initials>V.</ce:initials><ce:indexed-name>Bravou V.</ce:indexed-name><ce:surname>Bravou</ce:surname></author><author seq="3"><ce:initials>I.</ce:initials><ce:indexed-name>Petrou I.</ce:indexed-name><ce:surname>Petrou</ce:surname></author><author seq="4"><ce:initials>H.</ce:initials><ce:indexed-name>Kourea H.</ce:indexed-name><ce:surname>Kourea</ce:surname></author><author seq="5"><ce:initials>A.</ce:initials><ce:indexed-name>Mathioudakis A.</ce:indexed-name><ce:surname>Mathioudakis</ce:surname></author><author seq="6"><ce:initials>I.</ce:initials><ce:indexed-name>Lilis I.</ce:indexed-name><ce:surname>Lilis</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Lung</ref-sourcetitle><ref-publicationyear first="2013"/><ref-volisspag><voliss volume="191"/><pagerange first="511" last="521"/></ref-volisspag></ref-info><ref-fulltext>Gialmanidis IP, Bravou V, Petrou I, Kourea H, Mathioudakis A, Lilis I, et al. Expression of Bmi1, FoxF1, Nanog, and γ-catenin in relation to hedgehog signaling pathway in human non-small-cell lung cancer. Lung 2013; 191: 511-21</ref-fulltext></reference><reference id="16"><ref-info><ref-title><ref-titletext>Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">49949111381</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>Y.C.</ce:initials><ce:indexed-name>Chen Y.C.</ce:indexed-name><ce:surname>Chen</ce:surname></author><author seq="2"><ce:initials>H.S.</ce:initials><ce:indexed-name>Hsu H.S.</ce:indexed-name><ce:surname>Hsu</ce:surname></author><author seq="3"><ce:initials>Y.W.</ce:initials><ce:indexed-name>Chen Y.W.</ce:indexed-name><ce:surname>Chen</ce:surname></author><author seq="4"><ce:initials>T.H.</ce:initials><ce:indexed-name>Tsai T.H.</ce:indexed-name><ce:surname>Tsai</ce:surname></author><author seq="5"><ce:initials>C.K.</ce:initials><ce:indexed-name>How C.K.</ce:indexed-name><ce:surname>How</ce:surname></author><author seq="6"><ce:initials>C.Y.</ce:initials><ce:indexed-name>Wang C.Y.</ce:indexed-name><ce:surname>Wang</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>PLos One</ref-sourcetitle><ref-publicationyear first="2008"/><ref-volisspag><voliss volume="3"/><pagerange first="e2637"/></ref-volisspag></ref-info><ref-fulltext>Chen YC, Hsu HS, Chen YW, Tsai TH, How CK, Wang CY, et al. Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLos One 2008; 3: e2637</ref-fulltext></reference><reference id="17"><ref-info><ref-title><ref-titletext>Evidence for self-renewing lung cancer stem cells and their implications in tumor initiation, progression, and targeted therapy</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">77349109478</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>J.P.</ce:initials><ce:indexed-name>Sullivan J.P.</ce:indexed-name><ce:surname>Sullivan</ce:surname></author><author seq="2"><ce:initials>J.D.</ce:initials><ce:indexed-name>Minna J.D.</ce:indexed-name><ce:surname>Minna</ce:surname></author><author seq="3"><ce:initials>J.W.</ce:initials><ce:indexed-name>Shay J.W.</ce:indexed-name><ce:surname>Shay</ce:surname></author></ref-authors><ref-sourcetitle>Cancer Metastasis Rev</ref-sourcetitle><ref-publicationyear first="2010"/><ref-volisspag><voliss volume="29"/><pagerange first="61" last="72"/></ref-volisspag></ref-info><ref-fulltext>Sullivan JP, Minna JD, Shay JW. Evidence for self-renewing lung cancer stem cells and their implications in tumor initiation, progression, and targeted therapy. Cancer Metastasis Rev 2010; 29: 61-72</ref-fulltext></reference><reference id="18"><ref-info><ref-title><ref-titletext>Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">70349479538</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>G.</ce:initials><ce:indexed-name>Bertolini G.</ce:indexed-name><ce:surname>Bertolini</ce:surname></author><author seq="2"><ce:initials>L.</ce:initials><ce:indexed-name>Roz L.</ce:indexed-name><ce:surname>Roz</ce:surname></author><author seq="3"><ce:initials>P.</ce:initials><ce:indexed-name>Perego P.</ce:indexed-name><ce:surname>Perego</ce:surname></author><author seq="4"><ce:initials>M.</ce:initials><ce:indexed-name>Tortoeto M.</ce:indexed-name><ce:surname>Tortoeto</ce:surname></author><author seq="5"><ce:initials>E.</ce:initials><ce:indexed-name>Fontanella E.</ce:indexed-name><ce:surname>Fontanella</ce:surname></author><author seq="6"><ce:initials>L.</ce:initials><ce:indexed-name>Gatti L.</ce:indexed-name><ce:surname>Gatti</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Proc Natl Acad Sci</ref-sourcetitle><ref-publicationyear first="2009"/><ref-volisspag><voliss volume="106"/><pagerange first="16281" last="16286"/></ref-volisspag></ref-info><ref-fulltext>Bertolini G, Roz L, Perego P, Tortoeto M, Fontanella E, Gatti L, et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci 2009; 106: 16281-6</ref-fulltext></reference><reference id="19"><ref-info><ref-title><ref-titletext>Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">77951657935</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>D.J.</ce:initials><ce:indexed-name>Stewart D.J.</ce:indexed-name><ce:surname>Stewart</ce:surname></author></ref-authors><ref-sourcetitle>Crit Rev Oncol Hematol</ref-sourcetitle><ref-publicationyear first="2010"/><ref-volisspag><voliss volume="75"/><pagerange first="173" last="234"/></ref-volisspag></ref-info><ref-fulltext>Stewart DJ. Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. Crit Rev Oncol Hematol 2010; 75: 173-234</ref-fulltext></reference><reference id="20"><ref-info><ref-title><ref-titletext>Quantification of serum SOX2 DNA with FQ-PCR potentially provides a diagnostic biomarker for lung cancer</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84891863901</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>Y.</ce:initials><ce:indexed-name>Wu Y.</ce:indexed-name><ce:surname>Wu</ce:surname></author><author seq="2"><ce:initials>X.</ce:initials><ce:indexed-name>Du X.</ce:indexed-name><ce:surname>Du</ce:surname></author><author seq="3"><ce:initials>C.</ce:initials><ce:indexed-name>Xue C.</ce:indexed-name><ce:surname>Xue</ce:surname></author><author seq="4"><ce:initials>D.</ce:initials><ce:indexed-name>Li D.</ce:indexed-name><ce:surname>Li</ce:surname></author><author seq="5"><ce:initials>Q.</ce:initials><ce:indexed-name>Zheng Q.</ce:indexed-name><ce:surname>Zheng</ce:surname></author><author seq="6"><ce:initials>X.</ce:initials><ce:indexed-name>Li X.</ce:indexed-name><ce:surname>Li</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Med Oncol</ref-sourcetitle><ref-publicationyear first="2013"/><ref-volisspag><voliss volume="30"/><pagerange first="737"/></ref-volisspag></ref-info><ref-fulltext>Wu Y, Du X, Xue C, Li D, Zheng Q, Li X, et al. Quantification of serum SOX2 DNA with FQ-PCR potentially provides a diagnostic biomarker for lung cancer. Med Oncol 2013; 30: 737</ref-fulltext></reference><reference id="21"><ref-info><ref-title><ref-titletext>High SOX2 levels predict better outcome in non-small cell lung carcinomas</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84876432621</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>V.</ce:initials><ce:indexed-name>Velcheti V.</ce:indexed-name><ce:surname>Velcheti</ce:surname></author><author seq="2"><ce:initials>K.</ce:initials><ce:indexed-name>Schalper K.</ce:indexed-name><ce:surname>Schalper</ce:surname></author><author seq="3"><ce:initials>X.</ce:initials><ce:indexed-name>Yao X.</ce:indexed-name><ce:surname>Yao</ce:surname></author><author seq="4"><ce:initials>H.</ce:initials><ce:indexed-name>Cheng H.</ce:indexed-name><ce:surname>Cheng</ce:surname></author><author seq="5"><ce:initials>M.</ce:initials><ce:indexed-name>Kocoglu M.</ce:indexed-name><ce:surname>Kocoglu</ce:surname></author><author seq="6"><ce:initials>K.</ce:initials><ce:indexed-name>Dhodapkar K.</ce:indexed-name><ce:surname>Dhodapkar</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>PLoS One</ref-sourcetitle><ref-publicationyear first="2013"/><ref-volisspag><voliss volume="8"/><pagerange first="e61427"/></ref-volisspag></ref-info><ref-fulltext>Velcheti V, Schalper K, Yao X, Cheng H, Kocoglu M, Dhodapkar K, et al. High SOX2 levels predict better outcome in non-small cell lung carcinomas. PLoS One 2013; 8: e61427</ref-fulltext></reference><reference id="22"><ref-info><ref-title><ref-titletext>The prognostic value of SOX2 expression in non-small cell lung cancer: A meta-analysis</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84899038560</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>Y.</ce:initials><ce:indexed-name>Chen Y.</ce:indexed-name><ce:surname>Chen</ce:surname></author><author seq="2"><ce:initials>Y.</ce:initials><ce:indexed-name>Huang Y.</ce:indexed-name><ce:surname>Huang</ce:surname></author><author seq="3"><ce:initials>Y.</ce:initials><ce:indexed-name>Huang Y.</ce:indexed-name><ce:surname>Huang</ce:surname></author><author seq="4"><ce:initials>J.</ce:initials><ce:indexed-name>Chen J.</ce:indexed-name><ce:surname>Chen</ce:surname></author><author seq="5"><ce:initials>S.</ce:initials><ce:indexed-name>Wang S.</ce:indexed-name><ce:surname>Wang</ce:surname></author><author seq="6"><ce:initials>J.</ce:initials><ce:indexed-name>Zhou J.</ce:indexed-name><ce:surname>Zhou</ce:surname></author></ref-authors><ref-sourcetitle>PLoS One</ref-sourcetitle><ref-publicationyear first="2013"/><ref-volisspag><voliss volume="8"/><pagerange first="e71140"/></ref-volisspag></ref-info><ref-fulltext>Chen Y, Huang Y, Huang Y, Chen J, Wang S, Zhou J. The prognostic value of SOX2 expression in non-small cell lung cancer: a meta-analysis. PLoS One 2013; 8: e71140</ref-fulltext></reference><reference id="23"><ref-info><ref-title><ref-titletext>Elevated expression of SOX2 and FGFR1 in correlation with poor prognosis in patients with small cell lung cancer</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84888785481</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>F.</ce:initials><ce:indexed-name>Yang F.</ce:indexed-name><ce:surname>Yang</ce:surname></author><author seq="2"><ce:initials>Y.</ce:initials><ce:indexed-name>Gao Y.</ce:indexed-name><ce:surname>Gao</ce:surname></author><author seq="3"><ce:initials>J.</ce:initials><ce:indexed-name>Geng J.</ce:indexed-name><ce:surname>Geng</ce:surname></author><author seq="4"><ce:initials>D.</ce:initials><ce:indexed-name>Qu D.</ce:indexed-name><ce:surname>Qu</ce:surname></author><author seq="5"><ce:initials>Q.</ce:initials><ce:indexed-name>Han Q.</ce:indexed-name><ce:surname>Han</ce:surname></author><author seq="6"><ce:initials>J.</ce:initials><ce:indexed-name>Qi J.</ce:indexed-name><ce:surname>Qi</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>J Clin Exp Pathol</ref-sourcetitle><ref-publicationyear first="2013"/><ref-volisspag><voliss volume="6"/><pagerange first="2846" last="2854"/></ref-volisspag></ref-info><ref-fulltext>Yang F, Gao Y, Geng J, Qu D, Han Q, Qi J, et al. Elevated expression of SOX2 and FGFR1 in correlation with poor prognosis in patients with small cell lung cancer. Int J Clin Exp Pathol 2013; 6: 2846-54</ref-fulltext></reference><reference id="24"><ref-info><ref-title><ref-titletext>Coexpression of oct4 and nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">78650389774</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>S.H.</ce:initials><ce:indexed-name>Chiou S.H.</ce:indexed-name><ce:surname>Chiou</ce:surname></author><author seq="2"><ce:initials>M.L.</ce:initials><ce:indexed-name>Wang M.L.</ce:indexed-name><ce:surname>Wang</ce:surname></author><author seq="3"><ce:initials>Y.T.</ce:initials><ce:indexed-name>Chou Y.T.</ce:indexed-name><ce:surname>Chou</ce:surname></author><author seq="4"><ce:initials>C.J.</ce:initials><ce:indexed-name>Chen C.J.</ce:indexed-name><ce:surname>Chen</ce:surname></author><author seq="5"><ce:initials>C.F.</ce:initials><ce:indexed-name>Hong C.F.</ce:indexed-name><ce:surname>Hong</ce:surname></author><author seq="6"><ce:initials>W.J.</ce:initials><ce:indexed-name>Hsieh W.J.</ce:indexed-name><ce:surname>Hsieh</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Cancer Res</ref-sourcetitle><ref-publicationyear first="2010"/><ref-volisspag><voliss volume="70"/><pagerange first="10433" last="10444"/></ref-volisspag></ref-info><ref-fulltext>Chiou SH, Wang ML, Chou YT, Chen CJ, Hong CF, Hsieh WJ, et al. Coexpression of oct4 and nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Cancer Res 2010; 70: 10433-44</ref-fulltext></reference><reference id="25"><ref-info><ref-title><ref-titletext>Nuclear β-catenin accumulation is associated with increased expression of Nanog protein and predicts poor prognosis of non-small cell lung cancer</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84877030479</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>X.Q.</ce:initials><ce:indexed-name>Li X.Q.</ce:indexed-name><ce:surname>Li</ce:surname></author><author seq="2"><ce:initials>X.L.</ce:initials><ce:indexed-name>Yang X.L.</ce:indexed-name><ce:surname>Yang</ce:surname></author><author seq="3"><ce:initials>G.</ce:initials><ce:indexed-name>Zhang G.</ce:indexed-name><ce:surname>Zhang</ce:surname></author><author seq="4"><ce:initials>S.P.</ce:initials><ce:indexed-name>Wu S.P.</ce:indexed-name><ce:surname>Wu</ce:surname></author><author seq="5"><ce:initials>X.B.</ce:initials><ce:indexed-name>Deng X.B.</ce:indexed-name><ce:surname>Deng</ce:surname></author><author seq="6"><ce:initials>S.J.</ce:initials><ce:indexed-name>Xiao S.J.</ce:indexed-name><ce:surname>Xiao</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>J Transl Med</ref-sourcetitle><ref-publicationyear first="2013"/><ref-volisspag><voliss volume="11"/><pagerange first="114"/></ref-volisspag></ref-info><ref-fulltext>Li XQ, Yang XL, Zhang G, Wu SP, Deng XB, Xiao SJ, et al. Nuclear β-catenin accumulation is associated with increased expression of Nanog protein and predicts poor prognosis of non-small cell lung cancer. J Transl Med 2013; 11: 114</ref-fulltext></reference><reference id="26"><ref-info><ref-title><ref-titletext>Downregulation of KPNA2 in non-small-cell lung cancer is associated with Oct4 expression</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84884754337</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>X.L.</ce:initials><ce:indexed-name>Li X.L.</ce:indexed-name><ce:surname>Li</ce:surname></author><author seq="2"><ce:initials>L.L.</ce:initials><ce:indexed-name>Jia L.L.</ce:indexed-name><ce:surname>Jia</ce:surname></author><author seq="3"><ce:initials>M.M.</ce:initials><ce:indexed-name>Shi M.M.</ce:indexed-name><ce:surname>Shi</ce:surname></author><author seq="4"><ce:initials>X.</ce:initials><ce:indexed-name>Li X.</ce:indexed-name><ce:surname>Li</ce:surname></author><author seq="5"><ce:initials>L.</ce:initials><ce:indexed-name>Zh L.</ce:indexed-name><ce:surname>Zh</ce:surname></author><author seq="6"><ce:initials>H.F.</ce:initials><ce:indexed-name>Li H.F.</ce:indexed-name><ce:surname>Li</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>J Transl Med</ref-sourcetitle><ref-publicationyear first="2013"/><ref-volisspag><voliss volume="11"/><pagerange first="232"/></ref-volisspag></ref-info><ref-fulltext>Li XL, Jia LL, Shi MM, Li X, Li ZH, Li HF, et al. Downregulation of KPNA2 in non-small-cell lung cancer is associated with Oct4 expression. J Transl Med 2013; 11: 232</ref-fulltext></reference><reference id="27"><ref-info><ref-title><ref-titletext>SOX2 gene amplification and protein overexpression are associated with better outcome in squamous cell lung cancer</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">79959930090</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>T.</ce:initials><ce:indexed-name>Wilbertz T.</ce:indexed-name><ce:surname>Wilbertz</ce:surname></author><author seq="2"><ce:initials>P.</ce:initials><ce:indexed-name>Wagner P.</ce:indexed-name><ce:surname>Wagner</ce:surname></author><author seq="3"><ce:initials>K.</ce:initials><ce:indexed-name>Petersen K.</ce:indexed-name><ce:surname>Petersen</ce:surname></author><author seq="4"><ce:initials>A.C.</ce:initials><ce:indexed-name>Stiedl A.C.</ce:indexed-name><ce:surname>Stiedl</ce:surname></author><author seq="5"><ce:initials>V.J.</ce:initials><ce:indexed-name>Scheble V.J.</ce:indexed-name><ce:surname>Scheble</ce:surname></author><author seq="6"><ce:initials>S.</ce:initials><ce:indexed-name>Maier S.</ce:indexed-name><ce:surname>Maier</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Mod Pathol</ref-sourcetitle><ref-publicationyear first="2011"/><ref-volisspag><voliss volume="24"/><pagerange first="944" last="953"/></ref-volisspag></ref-info><ref-fulltext>Wilbertz T, Wagner P, Petersen K, Stiedl AC, Scheble VJ, Maier S, et al. SOX2 gene amplification and protein overexpression are associated with better outcome in squamous cell lung cancer. Mod Pathol 2011; 24: 944-53</ref-fulltext></reference><reference id="28"><ref-info><ref-title><ref-titletext>SOX2 oncogenes amplified and operate to activate AKT signaling in gastric cancer and predict immunotherapy responsiveness</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84904096678</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>Y.</ce:initials><ce:indexed-name>Tian Y.</ce:indexed-name><ce:surname>Tian</ce:surname></author><author seq="2"><ce:initials>X.</ce:initials><ce:indexed-name>Jia X.</ce:indexed-name><ce:surname>Jia</ce:surname></author><author seq="3"><ce:initials>S.</ce:initials><ce:indexed-name>Wang S.</ce:indexed-name><ce:surname>Wang</ce:surname></author><author seq="4"><ce:initials>Y.</ce:initials><ce:indexed-name>Li Y.</ce:indexed-name><ce:surname>Li</ce:surname></author><author seq="5"><ce:initials>P.</ce:initials><ce:indexed-name>Zhao P.</ce:indexed-name><ce:surname>Zhao</ce:surname></author><author seq="6"><ce:initials>D.</ce:initials><ce:indexed-name>Cai D.</ce:indexed-name><ce:surname>Cai</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>J Cancer Res Clin Oncol</ref-sourcetitle><ref-publicationyear first="2014"/><ref-volisspag><voliss volume="140"/><pagerange first="1117" last="1124"/></ref-volisspag></ref-info><ref-fulltext>Tian Y, Jia X, Wang S, Li Y, Zhao P, Cai D, et al. SOX2 oncogenes amplified and operate to activate AKT signaling in gastric cancer and predict immunotherapy responsiveness. J Cancer Res Clin Oncol 2014; 140: 1117-24</ref-fulltext></reference><reference id="29"><ref-info><ref-title><ref-titletext>The emerging role of SOX2 in cell proliferation and survival and its crosstalk with oncogenic signaling in lung cancer</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84887796196</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>Y.T.</ce:initials><ce:indexed-name>Chou Y.T.</ce:indexed-name><ce:surname>Chou</ce:surname></author><author seq="2"><ce:initials>C.C.</ce:initials><ce:indexed-name>Lee C.C.</ce:indexed-name><ce:surname>Lee</ce:surname></author><author seq="3"><ce:initials>S.H.</ce:initials><ce:indexed-name>Hsiao S.H.</ce:indexed-name><ce:surname>Hsiao</ce:surname></author><author seq="4"><ce:initials>S.E.</ce:initials><ce:indexed-name>Lin S.E.</ce:indexed-name><ce:surname>Lin</ce:surname></author><author seq="5"><ce:initials>S.C.</ce:initials><ce:indexed-name>Lin S.C.</ce:indexed-name><ce:surname>Lin</ce:surname></author><author seq="6"><ce:initials>C.H.</ce:initials><ce:indexed-name>Chung C.H.</ce:indexed-name><ce:surname>Chung</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Stem Cells</ref-sourcetitle><ref-publicationyear first="2013"/><ref-volisspag><voliss volume="31"/><pagerange first="2607" last="2619"/></ref-volisspag></ref-info><ref-fulltext>Chou YT, Lee CC, Hsiao SH, Lin SE, Lin SC, Chung CH, et al. The emerging role of SOX2 in cell proliferation and survival and its crosstalk with oncogenic signaling in lung cancer. Stem Cells 2013; 31: 2607-19</ref-fulltext></reference><reference id="30"><ref-info><ref-title><ref-titletext>SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">77952505658</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>T.</ce:initials><ce:indexed-name>Hussenet T.</ce:indexed-name><ce:surname>Hussenet</ce:surname></author><author seq="2"><ce:initials>S.</ce:initials><ce:indexed-name>Dali S.</ce:indexed-name><ce:surname>Dali</ce:surname></author><author seq="3"><ce:initials>J.</ce:initials><ce:indexed-name>Exinger J.</ce:indexed-name><ce:surname>Exinger</ce:surname></author><author seq="4"><ce:initials>B.</ce:initials><ce:indexed-name>Monga B.</ce:indexed-name><ce:surname>Monga</ce:surname></author><author seq="5"><ce:initials>B.</ce:initials><ce:indexed-name>Jost B.</ce:indexed-name><ce:surname>Jost</ce:surname></author><author seq="6"><ce:initials>D.</ce:initials><ce:indexed-name>Dembele D.</ce:indexed-name><ce:surname>Dembelé</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>PLoS One</ref-sourcetitle><ref-publicationyear first="2010"/><ref-volisspag><voliss volume="5"/><pagerange first="e8960"/></ref-volisspag></ref-info><ref-fulltext>Hussenet T, Dali S, Exinger J, Monga B, Jost B, Dembelé D, et al. SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas. PLoS One 2010; 5: e8960</ref-fulltext></reference><reference id="31"><ref-info><ref-title><ref-titletext>Increased SOX2 gene copy number is associated with FGFR1 and PIK3CA gene gain in non-small cell lung cancer and predicts improved survival in early stage disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84899669381</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>L.</ce:initials><ce:indexed-name>Toschi L.</ce:indexed-name><ce:surname>Toschi</ce:surname></author><author seq="2"><ce:initials>G.</ce:initials><ce:indexed-name>Finocchiaro G.</ce:indexed-name><ce:surname>Finocchiaro</ce:surname></author><author seq="3"><ce:initials>T.T.</ce:initials><ce:indexed-name>Nguyen T.T.</ce:indexed-name><ce:surname>Nguyen</ce:surname></author><author seq="4"><ce:initials>M.C.</ce:initials><ce:indexed-name>Skokan M.C.</ce:indexed-name><ce:surname>Skokan</ce:surname></author><author seq="5"><ce:initials>L.</ce:initials><ce:indexed-name>Giordano L.</ce:indexed-name><ce:surname>Giordano</ce:surname></author><author seq="6"><ce:initials>L.</ce:initials><ce:indexed-name>Gianoncelli L.</ce:indexed-name><ce:surname>Gianoncelli</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>PLoS One</ref-sourcetitle><ref-publicationyear first="2014"/><ref-volisspag><voliss volume="9"/><pagerange first="e95303"/></ref-volisspag></ref-info><ref-fulltext>Toschi L, Finocchiaro G, Nguyen TT, Skokan MC, Giordano L, Gianoncelli L, et al. Increased SOX2 gene copy number is associated with FGFR1 and PIK3CA gene gain in non-small cell lung cancer and predicts improved survival in early stage disease. PLoS One 2014; 9: e95303</ref-fulltext></reference><reference id="32"><ref-info><ref-title><ref-titletext>Detection of MET and SOX2 amplification by quantitative real-time PCR in non-small cell lung carcinoma</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">79551627806</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>Y.R.</ce:initials><ce:indexed-name>Cai Y.R.</ce:indexed-name><ce:surname>Cai</ce:surname></author><author seq="2"><ce:initials>H.Q.</ce:initials><ce:indexed-name>Zhang H.Q.</ce:indexed-name><ce:surname>Zhang</ce:surname></author><author seq="3"><ce:initials>Z.D.</ce:initials><ce:indexed-name>Zhang Z.D.</ce:indexed-name><ce:surname>Zhang</ce:surname></author><author seq="4"><ce:initials>J.</ce:initials><ce:indexed-name>Mu J.</ce:indexed-name><ce:surname>Mu</ce:surname></author><author seq="5"><ce:initials>L.</ce:initials><ce:indexed-name>Zh L.</ce:indexed-name><ce:surname>Zh</ce:surname></author></ref-authors><ref-sourcetitle>Oncol Lett</ref-sourcetitle><ref-publicationyear first="2011"/><ref-volisspag><voliss volume="2"/><pagerange first="257" last="264"/></ref-volisspag></ref-info><ref-fulltext>Cai YR, Zhang HQ, Zhang ZD, Mu J, Li ZH. Detection of MET and SOX2 amplification by quantitative real-time PCR in non-small cell lung carcinoma. Oncol Lett 2011; 2: 257-64</ref-fulltext></reference><reference id="33"><ref-info><ref-title><ref-titletext>Increased Sox2 copy number in lung squamous cell carcinomas</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84855385609</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>H.</ce:initials><ce:indexed-name>Sasaki H.</ce:indexed-name><ce:surname>Sasaki</ce:surname></author><author seq="2"><ce:initials>K.</ce:initials><ce:indexed-name>Yokota K.</ce:indexed-name><ce:surname>Yokota</ce:surname></author><author seq="3"><ce:initials>Y.</ce:initials><ce:indexed-name>Hikosaka Y.</ce:indexed-name><ce:surname>Hikosaka</ce:surname></author><author seq="4"><ce:initials>S.</ce:initials><ce:indexed-name>Moriyama S.</ce:indexed-name><ce:surname>Moriyama</ce:surname></author><author seq="5"><ce:initials>M.</ce:initials><ce:indexed-name>Yano M.</ce:indexed-name><ce:surname>Yano</ce:surname></author><author seq="6"><ce:initials>Y.</ce:initials><ce:indexed-name>Fujii Y.</ce:indexed-name><ce:surname>Fujii</ce:surname></author></ref-authors><ref-sourcetitle>Exp Ther Med</ref-sourcetitle><ref-publicationyear first="2012"/><ref-volisspag><voliss volume="3"/><pagerange first="44" last="48"/></ref-volisspag></ref-info><ref-fulltext>Sasaki H, Yokota K, Hikosaka Y, Moriyama S, Yano M, Fujii Y. Increased Sox2 copy number in lung squamous cell carcinomas. Exp Ther Med 2012; 3: 44-8</ref-fulltext></reference><reference id="34"><ref-info><ref-title><ref-titletext>Pulmonary adenocarcinoma in malignant pleural effusion enriches cancer stem cell properties during metastatic cascade</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84877065493</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>W.J.</ce:initials><ce:indexed-name>Chen W.J.</ce:indexed-name><ce:surname>Chen</ce:surname></author><author seq="2"><ce:initials>C.C.</ce:initials><ce:indexed-name>Ho C.C.</ce:indexed-name><ce:surname>Ho</ce:surname></author><author seq="3"><ce:initials>Y.L.</ce:initials><ce:indexed-name>Chang Y.L.</ce:indexed-name><ce:surname>Chang</ce:surname></author><author seq="4"><ce:initials>H.Y.</ce:initials><ce:indexed-name>Chen H.Y.</ce:indexed-name><ce:surname>Chen</ce:surname></author><author seq="5"><ce:initials>C.A.</ce:initials><ce:indexed-name>Lin C.A.</ce:indexed-name><ce:surname>Lin</ce:surname></author><author seq="6"><ce:initials>T.Y.</ce:initials><ce:indexed-name>Ling T.Y.</ce:indexed-name><ce:surname>Ling</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>PLoS One</ref-sourcetitle><ref-publicationyear first="2013"/><ref-volisspag><voliss volume="8"/><pagerange first="e54659"/></ref-volisspag></ref-info><ref-fulltext>Chen WJ, Ho CC, Chang YL, Chen HY, Lin CA, Ling TY, et al. Pulmonary adenocarcinoma in malignant pleural effusion enriches cancer stem cell properties during metastatic cascade. PLoS One 2013; 8: e54659</ref-fulltext></reference><reference id="35"><ref-info><ref-title><ref-titletext>Nanog, a novel prognostic marker for lung cancer</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84889631812</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>Y.</ce:initials><ce:indexed-name>Du Y.</ce:indexed-name><ce:surname>Du</ce:surname></author><author seq="2"><ce:initials>C.</ce:initials><ce:indexed-name>Ma C.</ce:indexed-name><ce:surname>Ma</ce:surname></author><author seq="3"><ce:initials>Z.</ce:initials><ce:indexed-name>Wang Z.</ce:indexed-name><ce:surname>Wang</ce:surname></author><author seq="4"><ce:initials>Z.</ce:initials><ce:indexed-name>Liu Z.</ce:indexed-name><ce:surname>Liu</ce:surname></author><author seq="5"><ce:initials>H.</ce:initials><ce:indexed-name>Liu H.</ce:indexed-name><ce:surname>Liu</ce:surname></author><author seq="6"><ce:initials>T.</ce:initials><ce:indexed-name>Wang T.</ce:indexed-name><ce:surname>Wang</ce:surname></author></ref-authors><ref-sourcetitle>Surg Oncol</ref-sourcetitle><ref-publicationyear first="2013"/><ref-volisspag><voliss volume="22"/><pagerange first="224" last="229"/></ref-volisspag></ref-info><ref-fulltext>Du Y, Ma C, Wang Z, Liu Z, Liu H, Wang T. Nanog, a novel prognostic marker for lung cancer. Surg Oncol 2013; 22: 224-9</ref-fulltext></reference><reference id="36"><ref-info><ref-title><ref-titletext>Expression of sox2 and oct4 and their clinical significance in human non-small-cell lung cancer</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84871682313</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>X.</ce:initials><ce:indexed-name>Li X.</ce:indexed-name><ce:surname>Li</ce:surname></author><author seq="2"><ce:initials>J.</ce:initials><ce:indexed-name>Wang J.</ce:indexed-name><ce:surname>Wang</ce:surname></author><author seq="3"><ce:initials>Z.</ce:initials><ce:indexed-name>Xu Z.</ce:indexed-name><ce:surname>Xu</ce:surname></author><author seq="4"><ce:initials>A.</ce:initials><ce:indexed-name>Ahmad A.</ce:indexed-name><ce:surname>Ahmad</ce:surname></author><author seq="5"><ce:initials>E.</ce:initials><ce:indexed-name>Li E.</ce:indexed-name><ce:surname>Li</ce:surname></author><author seq="6"><ce:initials>Y.</ce:initials><ce:indexed-name>Wang Y.</ce:indexed-name><ce:surname>Wang</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>J Mol Sci</ref-sourcetitle><ref-publicationyear first="2012"/><ref-volisspag><voliss volume="13"/><pagerange first="7663" last="7675"/></ref-volisspag></ref-info><ref-fulltext>Li X, Wang J, Xu Z, Ahmad A, Li E, Wang Y, et al. Expression of sox2 and oct4 and their clinical significance in human non-small-cell lung cancer. Int J Mol Sci 2012; 13: 7663-75</ref-fulltext></reference><reference id="37"><ref-info><ref-title><ref-titletext>Cell-free nucleic acids as biomarkers in cancer patients</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">79957458567</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>H.</ce:initials><ce:indexed-name>Schwarzenbach H.</ce:indexed-name><ce:surname>Schwarzenbach</ce:surname></author><author seq="2"><ce:initials>D.S.</ce:initials><ce:indexed-name>Hoon D.S.</ce:indexed-name><ce:surname>Hoon</ce:surname></author><author seq="3"><ce:initials>K.</ce:initials><ce:indexed-name>Pantel K.</ce:indexed-name><ce:surname>Pantel</ce:surname></author></ref-authors><ref-sourcetitle>Nat Rev Cancer</ref-sourcetitle><ref-publicationyear first="2011"/><ref-volisspag><voliss volume="11"/><pagerange first="426" last="437"/></ref-volisspag></ref-info><ref-fulltext>Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 2011; 11: 426-37</ref-fulltext></reference><reference id="38"><ref-info><ref-title><ref-titletext>Oncogenes and cancer</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">38749114995</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>C.M.</ce:initials><ce:indexed-name>Croce C.M.</ce:indexed-name><ce:surname>Croce</ce:surname></author></ref-authors><ref-sourcetitle>N Engl J Med</ref-sourcetitle><ref-publicationyear first="2008"/><ref-volisspag><voliss volume="358"/><pagerange first="502" last="511"/></ref-volisspag></ref-info><ref-fulltext>Croce CM. Oncogenes and cancer. N Engl J Med 2008; 358: 502-11</ref-fulltext></reference><reference id="39"><ref-info><ref-title><ref-titletext>The epigenomics of cancer</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">33847065486</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>P.A.</ce:initials><ce:indexed-name>Jones P.A.</ce:indexed-name><ce:surname>Jones</ce:surname></author><author seq="2"><ce:initials>S.B.</ce:initials><ce:indexed-name>Baylin S.B.</ce:indexed-name><ce:surname>Baylin</ce:surname></author></ref-authors><ref-sourcetitle>Cell</ref-sourcetitle><ref-publicationyear first="2007"/><ref-volisspag><voliss volume="128"/><pagerange first="683" last="692"/></ref-volisspag></ref-info><ref-fulltext>Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128: 683-92</ref-fulltext></reference><reference id="40"><ref-info><ref-title><ref-titletext>Reporting recommendations for tumor marker prognostic studies (REMARK): Explanation and elaboration</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84861543054</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>D.G.</ce:initials><ce:indexed-name>Altman D.G.</ce:indexed-name><ce:surname>Altman</ce:surname></author><author seq="2"><ce:initials>L.M.</ce:initials><ce:indexed-name>McShane L.M.</ce:indexed-name><ce:surname>McShane</ce:surname></author><author seq="3"><ce:initials>W.</ce:initials><ce:indexed-name>Sauerbrei W.</ce:indexed-name><ce:surname>Sauerbrei</ce:surname></author><author seq="4"><ce:initials>S.E.</ce:initials><ce:indexed-name>Taube S.E.</ce:indexed-name><ce:surname>Taube</ce:surname></author></ref-authors><ref-sourcetitle>PLoS Med</ref-sourcetitle><ref-publicationyear first="2012"/><ref-volisspag><voliss volume="9"/><pagerange first="e1001216"/></ref-volisspag></ref-info><ref-fulltext>Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration. PLoS Med 2012; 9: e1001216</ref-fulltext></reference><reference id="41"><ref-info><ref-title><ref-titletext>New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">57849117384</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>E.A.</ce:initials><ce:indexed-name>Eisenhauer E.A.</ce:indexed-name><ce:surname>Eisenhauer</ce:surname></author><author seq="2"><ce:initials>P.</ce:initials><ce:indexed-name>Therasse P.</ce:indexed-name><ce:surname>Therasse</ce:surname></author><author seq="3"><ce:initials>J.</ce:initials><ce:indexed-name>Bogaerts J.</ce:indexed-name><ce:surname>Bogaerts</ce:surname></author><author seq="4"><ce:initials>L.H.</ce:initials><ce:indexed-name>Schwartz L.H.</ce:indexed-name><ce:surname>Schwartz</ce:surname></author><author seq="5"><ce:initials>D.</ce:initials><ce:indexed-name>Sargent D.</ce:indexed-name><ce:surname>Sargent</ce:surname></author><author seq="6"><ce:initials>R.</ce:initials><ce:indexed-name>Ford R.</ce:indexed-name><ce:surname>Ford</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Eur J Cancer</ref-sourcetitle><ref-publicationyear first="2009"/><ref-volisspag><voliss volume="45"/><pagerange first="228" last="247"/></ref-volisspag></ref-info><ref-fulltext>Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47</ref-fulltext></reference><reference id="42"><ref-info><ref-title><ref-titletext>Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">82355191818</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>L.V.</ce:initials><ce:indexed-name>Sequist L.V.</ce:indexed-name><ce:surname>Sequist</ce:surname></author><author seq="2"><ce:initials>R.S.</ce:initials><ce:indexed-name>Heist R.S.</ce:indexed-name><ce:surname>Heist</ce:surname></author><author seq="3"><ce:initials>A.T.</ce:initials><ce:indexed-name>Shaw A.T.</ce:indexed-name><ce:surname>Shaw</ce:surname></author><author seq="4"><ce:initials>P.</ce:initials><ce:indexed-name>Fidias P.</ce:indexed-name><ce:surname>Fidias</ce:surname></author><author seq="5"><ce:initials>R.</ce:initials><ce:indexed-name>Rosovsky R.</ce:indexed-name><ce:surname>Rosovsky</ce:surname></author><author seq="6"><ce:initials>J.S.</ce:initials><ce:indexed-name>Temel J.S.</ce:indexed-name><ce:surname>Temel</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Ann Oncol</ref-sourcetitle><ref-publicationyear first="2011"/><ref-volisspag><voliss volume="22"/><pagerange first="2616" last="2624"/></ref-volisspag></ref-info><ref-fulltext>Sequist LV, Heist RS, Shaw AT, Fidias P, Rosovsky R, Temel JS, et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol 2011; 22: 2616-24</ref-fulltext></reference><reference id="43"><ref-info><ref-title><ref-titletext>Serum circulating human mRNA profiling and its utility for oral cancer detection</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">33645818727</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>Y.</ce:initials><ce:indexed-name>Li Y.</ce:indexed-name><ce:surname>Li</ce:surname></author><author seq="2"><ce:initials>D.</ce:initials><ce:indexed-name>Elashoff D.</ce:indexed-name><ce:surname>Elashoff</ce:surname></author><author seq="3"><ce:initials>M.</ce:initials><ce:indexed-name>Oh M.</ce:indexed-name><ce:surname>Oh</ce:surname></author><author seq="4"><ce:initials>U.</ce:initials><ce:indexed-name>Sinha U.</ce:indexed-name><ce:surname>Sinha</ce:surname></author><author seq="5"><ce:initials>M.A.</ce:initials><ce:indexed-name>St John M.A.</ce:indexed-name><ce:surname>St John</ce:surname></author><author seq="6"><ce:initials>X.</ce:initials><ce:indexed-name>Zhou X.</ce:indexed-name><ce:surname>Zhou</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>J Clin Oncol</ref-sourcetitle><ref-publicationyear first="2006"/><ref-volisspag><voliss volume="24"/><pagerange first="1754" last="1760"/></ref-volisspag></ref-info><ref-fulltext>Li Y, Elashoff D, Oh M, Sinha U, St John MA, Zhou X, et al. Serum circulating human mRNA profiling and its utility for oral cancer detection. J Clin Oncol 2006; 24: 1754-60</ref-fulltext></reference><reference id="44"><ref-info><ref-title><ref-titletext>Clinical impact of high-throughput gene expression studies in lung cancer</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">61549143718</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>J.</ce:initials><ce:indexed-name>Beane J.</ce:indexed-name><ce:surname>Beane</ce:surname></author><author seq="2"><ce:initials>A.</ce:initials><ce:indexed-name>Spira A.</ce:indexed-name><ce:surname>Spira</ce:surname></author><author seq="3"><ce:initials>M.E.</ce:initials><ce:indexed-name>Lenburg M.E.</ce:indexed-name><ce:surname>Lenburg</ce:surname></author></ref-authors><ref-sourcetitle>J Thorac Oncol</ref-sourcetitle><ref-publicationyear first="2009"/><ref-volisspag><voliss volume="4"/><pagerange first="109" last="118"/></ref-volisspag></ref-info><ref-fulltext>Beane J, Spira A, Lenburg ME. Clinical impact of high-throughput gene expression studies in lung cancer. J Thorac Oncol 2009; 4: 109-18</ref-fulltext></reference><reference id="45"><ref-info><ref-title><ref-titletext>Diversity of gene expression in adenocarcinoma of the lung</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">0035923583</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>M.E.</ce:initials><ce:indexed-name>Garber M.E.</ce:indexed-name><ce:surname>Garber</ce:surname></author><author seq="2"><ce:initials>O.G.</ce:initials><ce:indexed-name>Troyanskaya O.G.</ce:indexed-name><ce:surname>Troyanskaya</ce:surname></author><author seq="3"><ce:initials>K.</ce:initials><ce:indexed-name>Schluens K.</ce:indexed-name><ce:surname>Schluens</ce:surname></author><author seq="4"><ce:initials>S.</ce:initials><ce:indexed-name>Petersen S.</ce:indexed-name><ce:surname>Petersen</ce:surname></author><author seq="5"><ce:initials>Z.</ce:initials><ce:indexed-name>Thaesler Z.</ce:indexed-name><ce:surname>Thaesler</ce:surname></author><author seq="6"><ce:initials>M.</ce:initials><ce:indexed-name>Pacyna-Gengelbach M.</ce:indexed-name><ce:surname>Pacyna-Gengelbach</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Proc Natl Acad Sci U S A</ref-sourcetitle><ref-publicationyear first="2001"/><ref-volisspag><voliss volume="98"/><pagerange first="13784" last="13789"/></ref-volisspag></ref-info><ref-fulltext>Garber ME, Troyanskaya OG, Schluens K, Petersen S, Thaesler Z, Pacyna-Gengelbach M, et al. Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci U S A 2001; 98: 13784-9</ref-fulltext></reference><reference id="46"><ref-info><ref-title><ref-titletext>Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">0035923521</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>A.</ce:initials><ce:indexed-name>Bhattacharjee A.</ce:indexed-name><ce:surname>Bhattacharjee</ce:surname></author><author seq="2"><ce:initials>W.G.</ce:initials><ce:indexed-name>Richards W.G.</ce:indexed-name><ce:surname>Richards</ce:surname></author><author seq="3"><ce:initials>J.</ce:initials><ce:indexed-name>Staunton J.</ce:indexed-name><ce:surname>Staunton</ce:surname></author><author seq="4"><ce:initials>C.</ce:initials><ce:indexed-name>Li C.</ce:indexed-name><ce:surname>Li</ce:surname></author><author seq="5"><ce:initials>S.</ce:initials><ce:indexed-name>Monti S.</ce:indexed-name><ce:surname>Monti</ce:surname></author><author seq="6"><ce:initials>P.</ce:initials><ce:indexed-name>Vasa P.</ce:indexed-name><ce:surname>Vasa</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Proc Natl Acad Sci U S A</ref-sourcetitle><ref-publicationyear first="2001"/><ref-volisspag><voliss volume="98"/><pagerange first="13790" last="13795"/></ref-volisspag></ref-info><ref-fulltext>Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A 2001; 98: 13790-5</ref-fulltext></reference><reference id="47"><ref-info><ref-title><ref-titletext>Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">71549155909</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>S.</ce:initials><ce:indexed-name>Saigusa S.</ce:indexed-name><ce:surname>Saigusa</ce:surname></author><author seq="2"><ce:initials>K.</ce:initials><ce:indexed-name>Tanaka K.</ce:indexed-name><ce:surname>Tanaka</ce:surname></author><author seq="3"><ce:initials>Y.</ce:initials><ce:indexed-name>Toiyama Y.</ce:indexed-name><ce:surname>Toiyama</ce:surname></author><author seq="4"><ce:initials>T.</ce:initials><ce:indexed-name>Yokoe T.</ce:indexed-name><ce:surname>Yokoe</ce:surname></author><author seq="5"><ce:initials>Y.</ce:initials><ce:indexed-name>Okugawa Y.</ce:indexed-name><ce:surname>Okugawa</ce:surname></author><author seq="6"><ce:initials>Y.</ce:initials><ce:indexed-name>Ioue Y.</ce:indexed-name><ce:surname>Ioue</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Ann Surg Oncol</ref-sourcetitle><ref-publicationyear first="2009"/><ref-volisspag><voliss volume="16"/><pagerange first="3488" last="3498"/></ref-volisspag></ref-info><ref-fulltext>Saigusa S, Tanaka K, Toiyama Y, Yokoe T, Okugawa Y, Ioue Y, et al. Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy. Ann Surg Oncol 2009; 16: 3488-98</ref-fulltext></reference><reference id="48"><ref-info><ref-title><ref-titletext>Expression of androgen and estrogen signaling components and stem cell markers to predict cancer progression and cancer-specific survival in patients with metastatic prostate cancer</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84933577436</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>T.</ce:initials><ce:indexed-name>Fujimura T.</ce:indexed-name><ce:surname>Fujimura</ce:surname></author><author seq="2"><ce:initials>S.</ce:initials><ce:indexed-name>Takahashi S.</ce:indexed-name><ce:surname>Takahashi</ce:surname></author><author seq="3"><ce:initials>T.</ce:initials><ce:indexed-name>Urano T.</ce:indexed-name><ce:surname>Urano</ce:surname></author><author seq="4"><ce:initials>K.</ce:initials><ce:indexed-name>Takayama K.</ce:indexed-name><ce:surname>Takayama</ce:surname></author><author seq="5"><ce:initials>T.</ce:initials><ce:indexed-name>Sugihara T.</ce:indexed-name><ce:surname>Sugihara</ce:surname></author><author seq="6"><ce:initials>D.</ce:initials><ce:indexed-name>Obinata D.</ce:indexed-name><ce:surname>Obinata</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Clin Cancer Res</ref-sourcetitle><ref-publicationyear first="2014"/><ref-volisspag><voliss volume="20"/><pagerange first="4625" last="4635"/></ref-volisspag></ref-info><ref-fulltext>Fujimura T, Takahashi S, Urano T, Takayama K, Sugihara T, Obinata D, et al. Expression of androgen and estrogen signaling components and stem cell markers to predict cancer progression and cancer-specific survival in patients with metastatic prostate cancer. Clin Cancer Res 2014; 20: 4625-35</ref-fulltext></reference><reference id="49"><ref-info><ref-title><ref-titletext>Role of Sox2 and Oct4 in predicting survival of hepatocellular carcinoma patients after hepatectomy</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">79955860688</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>P.</ce:initials><ce:indexed-name>Huang P.</ce:indexed-name><ce:surname>Huang</ce:surname></author><author seq="2"><ce:initials>J.</ce:initials><ce:indexed-name>Qiu J.</ce:indexed-name><ce:surname>Qiu</ce:surname></author><author seq="3"><ce:initials>B.</ce:initials><ce:indexed-name>Li B.</ce:indexed-name><ce:surname>Li</ce:surname></author><author seq="4"><ce:initials>J.</ce:initials><ce:indexed-name>Hong J.</ce:indexed-name><ce:surname>Hong</ce:surname></author><author seq="5"><ce:initials>C.</ce:initials><ce:indexed-name>Lu C.</ce:indexed-name><ce:surname>Lu</ce:surname></author><author seq="6"><ce:initials>L.</ce:initials><ce:indexed-name>Wang L.</ce:indexed-name><ce:surname>Wang</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Clin Biochem</ref-sourcetitle><ref-publicationyear first="2011"/><ref-volisspag><voliss volume="44"/><pagerange first="582" last="589"/></ref-volisspag></ref-info><ref-fulltext>Huang P, Qiu J, Li B, Hong J, Lu C, Wang L, et al. Role of Sox2 and Oct4 in predicting survival of hepatocellular carcinoma patients after hepatectomy. Clin Biochem 2011; 44: 582-9</ref-fulltext></reference><reference id="50"><ref-info><ref-title><ref-titletext>Expression of OCT4 pseudogenes in human tumours: Lessons from glioma and breast carcinoma</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">79952550805</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>S.</ce:initials><ce:indexed-name>Zhao S.</ce:indexed-name><ce:surname>Zhao</ce:surname></author><author seq="2"><ce:initials>Q.</ce:initials><ce:indexed-name>Yuan Q.</ce:indexed-name><ce:surname>Yuan</ce:surname></author><author seq="3"><ce:initials>H.</ce:initials><ce:indexed-name>Hao H.</ce:indexed-name><ce:surname>Hao</ce:surname></author><author seq="4"><ce:initials>Y.</ce:initials><ce:indexed-name>Guo Y.</ce:indexed-name><ce:surname>Guo</ce:surname></author><author seq="5"><ce:initials>S.</ce:initials><ce:indexed-name>Liu S.</ce:indexed-name><ce:surname>Liu</ce:surname></author><author seq="6"><ce:initials>Y.</ce:initials><ce:indexed-name>Zhang Y.</ce:indexed-name><ce:surname>Zhang</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>J Pathol</ref-sourcetitle><ref-publicationyear first="2011"/><ref-volisspag><voliss volume="223"/><pagerange first="672" last="682"/></ref-volisspag></ref-info><ref-fulltext>Zhao S, Yuan Q, Hao H, Guo Y, Liu S, Zhang Y, et al. Expression of OCT4 pseudogenes in human tumours: lessons from glioma and breast carcinoma. J Pathol 2011; 223: 672-82</ref-fulltext></reference><reference id="51"><ref-info><ref-title><ref-titletext>Human Nanog pseudogene8 promotes the proliferation of gastrointestinal cancer cells</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84863775405</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>K.</ce:initials><ce:indexed-name>Uchino K.</ce:indexed-name><ce:surname>Uchino</ce:surname></author><author seq="2"><ce:initials>G.</ce:initials><ce:indexed-name>Hirano G.</ce:indexed-name><ce:surname>Hirano</ce:surname></author><author seq="3"><ce:initials>M.</ce:initials><ce:indexed-name>Hirahashi M.</ce:indexed-name><ce:surname>Hirahashi</ce:surname></author><author seq="4"><ce:initials>T.</ce:initials><ce:indexed-name>Isobe T.</ce:indexed-name><ce:surname>Isobe</ce:surname></author><author seq="5"><ce:initials>T.</ce:initials><ce:indexed-name>Shirakawa T.</ce:indexed-name><ce:surname>Shirakawa</ce:surname></author><author seq="6"><ce:initials>H.</ce:initials><ce:indexed-name>Kusaba H.</ce:indexed-name><ce:surname>Kusaba</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Exp Cell Res</ref-sourcetitle><ref-publicationyear first="2012"/><ref-volisspag><voliss volume="318"/><pagerange first="1799" last="1807"/></ref-volisspag></ref-info><ref-fulltext>Uchino K, Hirano G, Hirahashi M, Isobe T, Shirakawa T, Kusaba H, et al. Human Nanog pseudogene8 promotes the proliferation of gastrointestinal cancer cells. Exp Cell Res 2012; 318: 1799-807</ref-fulltext></reference></bibliography></tail></bibrecord></item></abstracts-retrieval-response>